US biotech major Regeneron (Nasdaq: REGN) has presented its financial results for the fourth quarter and full year 2025.

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended six novel medicines for approval at its ...

UK pharma major AstraZeneca is strengthening its weight management portfolio through a new strategic collaboration agreement ...

Cambridge, USA-based biotech Repertoire Immune Medicines has entered a strategic collaboration with US pharma major Eli Lilly ...

US biotech BioMarin Pharmaceutical (Nasdaq: BMRN) has priced an $850 million offering of 5.5% senior unsecured notes due 2034 ...

Privately-held Swedish neuropathic pain specialist PharmNovo has announced changes to its board of directors, welcoming two ...

US ophthalmology company SpyGlass Pharma has set out the terms of an initial public offering (IPO) in which the firms hopes ...

Belgian biotech Agomab Therapeutics has set the terms for its planned US initial public offering, according to a filing with ...

South Korea’s Samsung Bioepis says it has signed a settlement and license agreement with Regeneron and Bayer concerning the commercialization of SB15, a biosimilar to Eylea 2mg (aflibercept 40mg/mL ...

The US Food and Drug Administration has accepted Summit Therapeutics’ (Nasdaq: SMMT) application for ivonescimab plus ...

Germany-based Vetter Pharma has confirmed its plans to build a state-of-the-art production facility in the Saarland region of southwest Germany.

Italian pharma major Recordati has entered into a collaboration and license agreement with US mRNA specialist Moderna to develop and commercialize worldwide mRNA-3927, an investigational product for ...